Search results
Results from the WOW.Com Content Network
NVAX data by YCharts. Novavax's late-stage trials hit a snag. Novavax successfully developed a COVID-19 vaccine that is currently its only product on the market. The company has been working on ...
An hour before the market closed Thursday, as news reports of Trump’s choice began trickling out, Covid-19 vaccine maker Moderna dipped as much as 6%, and Pfizer fell almost 2%.
Kennedy has long railed against vaccines, once calling those that protect against Covid-19 a "crime against humanity." He has treaded more carefully in recent weeks, though, and has said he wouldn ...
Moderna cut its 2025 forecast by $1 billion Monday, citing weak demand for its newest vaccine as well as slow sales for its COVID-19 vaccine.The company now expects $1.5 to $2 billion in revenue ...
Investors are "spooked" by plan to name a vaccine-sceptic as US health secretary, analysts say. ... acknowledging that the uncertainty had hit share prices. ... My top 10 stocks to buy in 2024 are ...
One stock that just can't seem to catch a break of late is Pfizer (NYSE: PFE). Given how well Pfizer has performed in recent years due to its COVID-19 vaccine and pill (its revenue topped $100 ...
Trump said during a rally in late October that he would let Kennedy “go wild” on healthcare in the country, and vaccine stocks like Moderna and Novavax have been heading lower since. Thursday ...
Stocks of coronavirus vaccine could run out at the end of January unless new ones such as the Oxford jab are approved, a former minister has warned. Former health secretary Jeremy Hunt told the ...